Background
Methods
Study design, setting, and subjects
Treatment algorithm
Outcome measurements
Cytokine profiles in MIS-C
Statistical analyses
Results
Patient demographics
Parameter | All MIS-C | IVIG monotherapy | All IVIG + anakinra | p-value |
---|---|---|---|---|
Patients (n, %) | 46, 100% | 14, 30% | 32, 70% | N/A |
Demographics
| ||||
Age, in years [Q1, Q3] | 8 [4,13] | 10.5 [3.5, 13] | 8 [4, 10] | 0.57 |
Male (n, %) | 25, 54% | 8, 57% | 17, 53% | > 0.99 |
African American (n, %) | 25, 54% | 8, 57% | 17, 53% | > 0.99 |
Latin-American (n, %) | 20, 43% | 6, 43% | 14, 44% | > 0.99 |
Caucasian (n, %) | 1, 2% | 0, 0% | 1, 3% | > 0.99 |
MIS-C clinical features
| ||||
SARS-CoV2 PCR + (n, %) | 19, 41% | 5, 36% | 14, 44% | 0.75 |
Non-specific (n, %) | 15, 33% | 9, 64% | 6, 19% | 0.005 |
KD-like (n, %) | 20, 43% | 3, 21% | 17, 53% | 0.06 |
CV shock (n, %) | 23, 50% | 3, 21% | 20, 63% | 0.02 |
KDSS-like (n, %) | 12, 26% | 1, 7% | 11, 34% | 0.07 |
Medications
| ||||
IVIG (n, %) | 46, 100% | 14, 100% | 32, 100% | N/A |
Inflammatory steroids (n, %) | 3, 7% | 0, 0% | 3, 9% | 0.54 |
Stress hydrocortisone (n, %) | 7, 15% | 1, 7% | 6, 19% | 0.41 |
Characteristics of MIS-C patients who received IVIG+anakinra
Parameter | - CV shock | + CV shock | p-value |
---|---|---|---|
Patients (n, %) | 12, 38% | 20, 63% | N/A |
Medications
| |||
Inflammatory steroids (n, %) | 0, 0% | 3, 15% | 0.27 |
Stress hydrocortisone (n, %) | 0, 0% | 6, 30% | 0.06 |
Anakinra treatment characteristics
| |||
Adjunct therapy (n, %) | 0, 0% | 20, 100% | N/A |
First-line rescue therapy (n, %) | 12, 100% | 0, 0% | N/A |
Starting dose, mg/kg/day [Q1, Q3] | 7.7 [4.5, 8.0] | 7.9 [7.7, 9.9] | 0.09 |
Initiation, hospitalization day [Q1, Q3] | 2.0 [2.0, 4.8] | 2.0 [1.0, 3.0] | 0.11 |
Max dose, mg/kg/day [Q1, Q3] | 8.0 [4.5, 9.2] | 9.8 [8.1, 10.0] | 0.003 |
Max dose, mg/dose [Q1, Q3] | 41 [30, 94] | 55 [46, 100] | 0.21 |
Treatment duration, days [Q1, Q3] | 7.1 [4.6, 8.8] | 10.6 [9.7, 13.3] | 0.002 |
Resolution of fever in MIS-C patients
Longitudinal cardiac function measurements in MIS-C patients
Adverse events
Adverse event | IVIG monotherapy (n = 14) | IVIG + anakinra without CS (n = 25) | IVIG + anakinra with CS (n = 9) | p-value |
---|---|---|---|---|
Elevated LFTs (n %) | 2, 14% | 6, 24% | 7, 67% | 0.008* |
Neutropenia (n %) | 1, 7% | 5, 20% | 3, 33% | 0.36 |
Hemolytic anemia (n %) | 1, 7% | 1, 4% | 1, 11% | 0.73 |
Anaphylaxis (n %) | 0, 0% | 0, 0% | 0, 0% | N/A |
Rash (n %) | 0, 0% | 2, 8% | 0, 0% | 0.42 |
Re-hospitalization (n %) | 0, 0% | 0, 0% | 0, 0% | N/A |
Comparison of cytokine profiles in MIS-C patients in the IVIG monotherapy and IVIG + anakinra groups
Cytokines, fold difference [Q1, Q3] | All MIS-C | IVIG monotherapy | All IVIG + anakinra | p-value |
---|---|---|---|---|
IFNγ | 1.0 [0.4–1.6] | 0.4 [0.40–1.2] | 1.0 [0.5–2.1] | 0.07 |
IL-1β | 0.9 [0.2–1.0] | 0.9 [0.7–0.9] | 0.9 [0.2–1.0] | 0.37 |
IL-2 | 1.0 [1.0–1.0] | 1.0 [1.0–1.0] | 1.0 [1.0–1.0] | 0.74 |
IL-6 | 14.3 [3.2–34.4] | 3.0 [1.6–15.8] | 22.1 [9.9–39.0] | 0.006 |
IL-8 | 0.6 [0.3–1.0] | 0.3 [0.3–0.6] | 1.0 [0.3–1.0] | 0.03 |
IL-12 | 0.4 [0.4–1.0] | 0.4 [0.4–0.4] | 0.7 [0.4–1.0] | 0.10 |
IL-17 | 1.0 [0.6–1.6] | 1.0 [0.6–3.0] | 1.0 [0.6–1.0] | 0.98 |
sIL-2R | 4.0 [2.0–6.7] | 1.4 [0.9–3.2] | 5.7 [3.7–7.8] | 0.0006 |
TNFα | 0.3 [0.1–0.5] | 0.2 [0.1–0.3] | 0.3 [0.2–0.6] | 0.11 |